Related references
Note: Only part of the references are listed.DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with Plasmodium falciparum
Katharine A. Collins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation
Sean C. Murphy et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study
Alejandro Llanos-Cuentas et al.
LANCET INFECTIOUS DISEASES (2018)
A Molecular Assay to Quantify Male and Female Plasmodium falciparum Gametocytes: Results From 2 Randomized Controlled Trials Using Primaquine for Gametocyte Clearance
Will Stone et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study
James S. McCarthy et al.
LANCET INFECTIOUS DISEASES (2017)
DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection
Mihly Sulyok et al.
LANCET INFECTIOUS DISEASES (2017)
Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development
James S. McCarthy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers
James S. McCarthy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial
Aung Pyae Phyo et al.
LANCET INFECTIOUS DISEASES (2016)
A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study
James S. McCarthy et al.
MALARIA JOURNAL (2016)
Evaluating the Pharmacodynamic Effect of Antimalarial Drugs in Clinical Trials by Quantitative PCR
Louise Marquart et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Malaria medicines: a glass half full?
Timothy N. C. Wells et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria
Margaret A. Phillips et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials
Joerg J. Moehrle et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Experimentally Induced Blood-Stage Plasmodium vivax Infection in Healthy Volunteers
James S. McCarthy et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Designing the next generation of medicines for malaria control and eradication
Jeremy N. Burrows et al.
MALARIA JOURNAL (2013)
A real-time, quantitative PCR method using hydrolysis probes for the monitoring of Plasmodium falciparum load in experimentally infected human volunteers
Rebecca J. Rockett et al.
MALARIA JOURNAL (2011)
A Pilot Randomised Trial of Induced Blood-Stage Plasmodium falciparum Infections in Healthy Volunteers for Testing Efficacy of New Antimalarial Drugs
James S. McCarthy et al.
PLOS ONE (2011)
Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria
Susan A. Charman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Muscular exercise can cause highly pathological liver function tests in healthy men
Jonas Pettersson et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2008)